Systemic administration of RTC13 showed to be able to restore dystrophin expression in virtually every muscle analyzed including diaphragm and heart, two of the muscles that are most affected in DMD patients and that are proven to be the most difficult to target by the majority of the therapeutic approaches currently under development. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.